TY - JOUR
T1 - Anti-paternal antibodies by flow cytometry in the management of alloimmunization on recurrent miscarriages
AU - Matsubayashi, Hidehiko
AU - Maruyama, Tetsuo
AU - Ozawa, Nobuaki
AU - Izumi, Shun Ichiro
AU - Sugi, Toshitaka
AU - Yoshikata, Kikuo
AU - Yoshimura, Yasunori
AU - Makino, Tsunehisa
PY - 2000
Y1 - 2000
N2 - Problem: There is no reliable laboratory test available to diagnose immunologically mediated miscarriages. We investigated the clinical significance of maternal anti-paternal leukocyte antibodies by flow cytometry after alloimmunization. Method of study: The flow cytometry crossmatch (FCXM) was performed in 158 patients with a history of three or more unexplained first-trimester miscarriages without live birth. After negative FCXM patients were immunized, subsequent pregnancy outcomes and FCXM results were followed. Results: Of 112 subsequent pregnancies, 83 of 100 (83.0%) FCXM-positive patien ts after immunotherapy had successful pregnancy outcomes, whereas seven of 10 (70.0%) FCXM-negative patients had miscarriages (P = 0.0001). The percent live birth ratio was 2.77 (CI, 1.07-7.16; P = 0.0001) for FCXM-positive patients compared to FCXM-negative patients. The calculated predictive value showed that 75.6% of FCXM-negative patients would have subsequent miscarriages. Conclusions: Positive FCXM is closely associated with successful pregnancy outcome following immunotherapy. We propose that FCXM might be included in the routine laboratory tests for the management of recurrent miscarriages.
AB - Problem: There is no reliable laboratory test available to diagnose immunologically mediated miscarriages. We investigated the clinical significance of maternal anti-paternal leukocyte antibodies by flow cytometry after alloimmunization. Method of study: The flow cytometry crossmatch (FCXM) was performed in 158 patients with a history of three or more unexplained first-trimester miscarriages without live birth. After negative FCXM patients were immunized, subsequent pregnancy outcomes and FCXM results were followed. Results: Of 112 subsequent pregnancies, 83 of 100 (83.0%) FCXM-positive patien ts after immunotherapy had successful pregnancy outcomes, whereas seven of 10 (70.0%) FCXM-negative patients had miscarriages (P = 0.0001). The percent live birth ratio was 2.77 (CI, 1.07-7.16; P = 0.0001) for FCXM-positive patients compared to FCXM-negative patients. The calculated predictive value showed that 75.6% of FCXM-negative patients would have subsequent miscarriages. Conclusions: Positive FCXM is closely associated with successful pregnancy outcome following immunotherapy. We propose that FCXM might be included in the routine laboratory tests for the management of recurrent miscarriages.
KW - Complement-dependent cytotoxicity
KW - Flow cytometry crossmatch
KW - Immunologically mediated miscarriages
KW - Immunotherapy
UR - http://www.scopus.com/inward/record.url?scp=0033647284&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033647284&partnerID=8YFLogxK
U2 - 10.1111/j.8755-8920.2000.440506.x
DO - 10.1111/j.8755-8920.2000.440506.x
M3 - Article
C2 - 11125790
AN - SCOPUS:0033647284
SN - 8755-8920
VL - 44
SP - 284
EP - 288
JO - American Journal of Reproductive Immunology
JF - American Journal of Reproductive Immunology
IS - 5
ER -